Abstract No. 236 Outcomes by Key Prognostic Factors in EMERALD-1: A Phase 3 Study of Durvalumab ± Bevacizumab with Transarterial Chemoembolization (TACE) in Participants with Embolization-Eligible Unresectable Hepatocellular Carcinoma (Uhcc)